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spirin and the Prevention
f Cardiovascular Disease
n Chronic Kidney Disease
ime to Move Forward?*
avinder K. Wali, MD
airfax, Virginia
hronic kidney disease (CKD) is a common global public
ealth problem. More than 500 million people worldwide—
bout 1 in 10 adults—have some form of kidney damage
1). In the U.S., an estimated 20 million people have CKD,
nd this number is believed to be increasing exponentially
ithin an aging population (2).
See page 956
Numerous epidemiological studies have consistently
emonstrated that persons with CKD are at risk of devel-
ping cardiovascular disease (CVD) events (3–6). Persons
ith CKD who have an acute coronary event fare worse
han persons who do not have CKD, despite optimal
reatment (7,8). Persons with CKD oftentimes die of
VD-related events long before there is significant progres-
ion in their CKD and the need for either dialysis or kidney
ransplantation arises.
The spectrum of CVD in persons with CKD is perhaps
ore complex than CVD in the general population because
KD patients have specific comorbidities that develop and
rogress due to the metabolic complexity of CKD (9).
ne critical component of CVD in the CKD population
s the development of accelerated atherosclerosis (10,11).
s in the general population, atherosclerotic disease can
emain asymptomatic for a variable period of time (12) in
atients with CKD, and then—for as yet poorly under-
tood reasons—it can suddenly change course with the
evelopment of thrombosis. This change toward athero-
hrombosis (13) is the harbinger for the development of
cute vascular events, including sudden death (12–14).
latelet adhesion, aggregation, and activation play a critical
ole in the development and progression of atheromatous
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r other antiplatelet agents is crucial in the prevention of
hrombus formation as well as thrombus progression.
A meta-analysis of randomized clinical trials (15) and
bservational studies in high-risk patients (with established
VD) have demonstrated that long-term treatment with a
ingle daily dose of aspirin typically prevents at least 10 to 20
atal and nonfatal vascular events for every 1,000 patients
uring a 1-year treatment period. Conversely, the risk of
ajor bleeding complications with low-dose aspirin therapy
as 1 to 2 per 1,000 patients for 1 year, and with the
bsolute number of hemorrhagic strokes being 1 to 2 per
0,000 patients. Hence, on balance, the benefits outweigh
he risks (15).
The studies of single-dose aspirin therapy for the primary
revention of CVD events in low- and intermediate-risk
opulations over the past 3 decades have generated diver-
ent results. The current recommendations for the use of
ow-dose aspirin in the primary prevention of CVD events
n persons without underlying CVD or at low risk for the
evelopment of these events is fraught with inconsistencies
15–18). However, a recent meta-analysis that evaluated
nd analyzed individual patient data, compared with earlier
eta-analyses that only included aggregate data (15), con-
luded that the use of aspirin was associated with only a 20%
eduction in nonfatal myocardial infarction and without any
enefit with regard to fatal infarcts, different types of
trokes, and vascular deaths, while there was a statistically
ignificant increase in the risk for major gastrointestinal and
xtracranial bleeds (absolute increased risk of 0.03% per
ear) (17).
In this issue, Jardine et al. (19) explored the interesting
nd challenging clinical dilemma of whether low-dose
spirin therapy can prevent cardiovascular disease events in
atients with different stages of CKD. They stratified
nrollees of the HOT (Hypertension Optimal Treatment)
rial by estimated glomerular filtration rate (eGFR) calcu-
ated from their baseline creatinine levels obtained at dif-
erent centers at the time of randomization. They then
xamined the effects of aspirin therapy (75 mg/day) versus
lacebo on the risk of cardiovascular events in 3,619
ypertensive persons who also had CKD (eGFR 60
l/min/1.73 m2) at the time of enrollment. Overall, use of
ow-dose aspirin compared with placebo over a mean
ollow-up period of nearly 4 years resulted in an absolute
isk reduction of major CVD events by 0.28%, 0.74%, and
7% in the different eGFR groups (60, 45 to 59, and45
l/min/1.73 m2), respectively. As is evident, the most
otable impact was in the group with advanced CKD
eGFR 45 ml/min/1.73 m2). Contrary to the results of
eta-analyses of other primary prevention trials (17), Jar-
ine et al. (19), in fact, showed that all-cause mortality,
ardiovascular mortality, and strokes were prevented by
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September 14, 2010:966–8 Cardiovascular Disease in CKDncrease the risk of major bleeding; however, and perhaps
urprisingly, this complication was not any higher in the
owest eGFR group, as one may have expected. Use of
ow-dose aspirin for CKD was associated with major bleed-
ng in 27 per 1,000 persons and minor bleeding in 12 per
,000 persons in the low eGFR group. Unfortunately, since
he HOT study did not categorize the types of stroke, we do
ot know if any of the major bleeding events included
emorrhagic stroke, and this is a cause for concern in the
KD population with their increased risk for bleeding
20,21). The risk of major and minor bleeding in CKD
ubgroups as reported by Jardine et al. (19) was nearly 10
imes higher than what has been reported for the general
opulation (15).
To put the findings of Jardine et al. (19) into context, it
s interesting to examine how the results of this study
ompare with other studies of low-dose aspirin therapy in a
igh-risk population other than the CKD population.
It is well known that the presence of diabetes mellitus
types 1 and 2) is considered to be a “CAD equivalent.” At
resent, the American Diabetic Association and the Amer-
can Heart Association recommend aspirin therapy for all
iabetic patients older than 40 years of age. Ogawa et al.
22), in the JPAD (Japanese Primary Prevention of Athero-
clerosis With Aspirin for Diabetics) study, randomized
ype 2 diabetic patients without a history of atherosclerotic
isease to low-dose aspirin therapy (80 to 100 mg/day)
ersus placebo. During a median follow-up of 4 years,
spirin therapy did not confer benefit for any CVD events or
or total mortality. Only the subgroup analysis of patients 65
ears of age or older showed a trend toward a benefit with
ow-dose aspirin therapy for the primary end point (hazard
atio: 0.68; 95% confidence interval: 0.46 to 0.99) compared
ith the control group of a similar age. An important and
otable finding of this study was that aspirin therapy was
ssociated with an increased risk of gastrointestinal and
etinal bleeding as well as the need for blood transfusions
22). One important caveat of this trial was that the study
ay have been underpowered. However, another study, the
OPADAD (Prevention of Progression of Arterial Disease
nd Diabetes) trial comparing low-dose aspirin with placebo
or type 2 diabetic patients with asymptomatic peripheral
ascular disease (23) again demonstrated no benefit associ-
ted with low-dose aspirin.
Peripheral vascular disease, even without underlying dia-
etes, is considered a risk factor for cardiac events and
trokes. A meta-analysis of 18 randomized controlled clin-
cal trials assessing the effect of aspirin therapy, either alone
r with dipyridamole, in 5,269 patients with peripheral
ascular disease did not show any benefit in the primary
utcome measure of cardiovascular events (nonfatal myo-
ardial infarction, nonfatal stroke, or cardiovascular death),
ut did show a statistically significant reduction in nonfatal
trokes (24). Fowkes et al. (25) similarly reported lack of
enefit in the prevention of vascular events in a randomized
ontrol study of asymptomatic atherosclerosis that randomly kllocated 3,350 men and women with screening ankle-
rachial index 0.95 to aspirin versus placebo.
When it comes to patients with CKD, the effect of
spirin in the primary prevention of cardiovascular disease in
his population has remained completely unexplored and
nproven. Jardine et al. (19) should be commended for
emonstrating that persons with CKD might be more
menable to prevention of CVD events with aspirin therapy
han is the population at large, and perhaps even more
menable to such therapy than other high-risk groups, such
s those with diabetes mellitus (22,23) or peripheral vascular
isease (24,25)—albeit, with an increased risk of bleeding
omplications. It is noteworthy that the presented post-hoc
nalysis is of enrollees in the HOT study who mostly
95%) did not have baseline CVD, and 10% had
iabetes mellitus. On the basis of these demographics, the
tudy by Jardine et al. (19) essentially serves as a surrogate
or a primary CVD prevention trial in persons with CKD.
Nevertheless, results of subgroup analysis should always
e interpreted with caution, and several factors must be
onsidered when interpreting the results of Jardine et al.
19). 1) The present post-hoc analysis should not be taken
s robust evidence in favor of aspirin therapy for persons
ith CKD. 2) The results of this study should be used to
enerate a hypothesis for a well-designed and appropriately
owered study including patients with all stages of CKD. 3)
ost-hoc and subgroup analyses are limited with regard to
btaining reliable estimates of risks for common as well as
or rare adverse events. However, the results of this study
an be used to estimate the sample size needed to evaluate
hether low-dose aspirin or the use of other antiplatelet
gents is safe in this population. The risk of major bleeding
s well as paradoxical thrombosis is a genuine concern when
sing aspirin therapy for patients with CKD (21).
An effective and safe preventive therapy that may abro-
ate CVD events in patients with CKD could decrease the
urden of health care costs, not only by preventing the event
er se, but also by avoiding complications associated with
he event or due to interventions needed to treat the event
26). Although CVD is highly prevalent among persons
ith different stages of CKD, clinical trial data of patients
ith CVD in the general population but without other
omorbidities are not necessarily generalizable to the CKD
opulation, as has been recently demonstrated in other
tudies involving other high-risk patients (22,23). The
ncreased burden of concomitant metabolic and biological
haracteristics that clearly distinguish persons with CKD (9)
ould surely influence their response to preventive therapies
s well as to other interventions (26).
Now it is time to move forward. For the reasons dis-
ussed, the results presented by Jardine et al. (19) should
ncourage prospective high-quality clinical trials to allow us
o develop evidence-based guidelines for the prevention of
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